Skip to main content

CL10027 Laser Ablation of Abnormal Neurological Tissue using Robotic Neuroblate system (LAANTERN) Prospective Registry.

NCT02392078

Laser Ablation of Abnormal Neurological Tissue using Robotic Neuroblate system (LAANTERN) Prospective Registry.

Associated Conditions

Surgery

Principal Investigator

James Baumgartner

Sponsor

Monteris Medical

This registry is post-market multi-center designed to collect medical history, procedure, and follow-up information on patients that are already scheduled to be treated with NeuroBlate System in observational manner. The purpose of this registry is to understand how the NeuroBlate System is working and used in current standard of care. Since it received FDA clearance in April 2013, the NeuroBlate System has been used in over 300 procedures conducted at approximately 20 leading institutions across United States. Limited clinical outcome and quality of life data is available on NeuroBlate System with the use of laser energy to destroy soft tissues like brain tumors.

This study is currently enrolling.